CD276 and glioblastoma: Furthermore, a recent clinical letter outlined the administration of B7-H3 CAR T cells to a 56-year-old woman with recurrent GBM, highlighting a potent but short-term anti-tumor response in situ, absent of grade 3 or higher toxicities associated with CAR T cell infusion [94].